HEME-20

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD) (HEME-20)

What's the purpose of the trial?

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

Trial status

Accepting patients

Phase

Pilot Trial

Enrollment

Last Updated

2 weeks ago

Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Experimental Arm: Bone Marrow Minimal Residual Disease Negative

Accepting patients

Experimental Arm: Bone Marrow Minimal Residual Disease Positive

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.